Cancer Immunology, Immunotherapy

, Volume 53, Issue 3, pp 187–195

The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy

  • Harpreet Singh-Jasuja
  • Niels P. N. Emmerich
  • Hans-Georg Rammensee
Review

DOI: 10.1007/s00262-003-0480-x

Cite this article as:
Singh-Jasuja, H., Emmerich, N.P.N. & Rammensee, HG. Cancer Immunol Immunother (2004) 53: 187. doi:10.1007/s00262-003-0480-x

Abstract

There is substantial need for molecularly defined tumor antigens to prime cytotoxic T cells in vivo for cancer immunotherapy, especially in the case of tumor entities for which only a few tumor antigens have been defined so far. In this review, we present the “Tübingen approach” to identify, select, and validate large numbers of MHC/HLA class I–associated peptides derived from tumor-associated antigens. Step 1 is the identification of naturally presented HLA-associated peptides directly from primary tumor cells. Step 2 is selection of tumor-associated peptides from step 1 by differential gene expression analysis and data mining. Step 3 is validation of selected candidates by monitoring in vivo T-cell responses in the context of patient-individualized immunizations. Our approach combines methods from genomics, proteomics, bioinformatics, and T-cell immunology. The aim is to develop effective immunotherapeutics consisting of multiple tumor-associated epitopes in order to induce a broad and specific immune response against cancer cells.

Keywords

Tuebingen approach Tumor-associated HLA peptides Cancer therapy 

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Harpreet Singh-Jasuja
    • 1
    • 2
  • Niels P. N. Emmerich
    • 2
  • Hans-Georg Rammensee
    • 1
  1. 1.Department of Immunology, Institute for Cell BiologyUniversity of TübingenTübingenGermany
  2. 2.Immatics BiotechnologiesTübingenGermany

Personalised recommendations